Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Get Free Report) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.08 and traded as high as $0.09. Bellicum Pharmaceuticals shares last traded at $0.07, with a volume of 6,000 shares.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Bellicum Pharmaceuticals in a report on Tuesday. They issued a “sell” rating for the company.
Read Our Latest Stock Report on BLCM
Bellicum Pharmaceuticals Stock Down 6.6 %
Hedge Funds Weigh In On Bellicum Pharmaceuticals
An institutional investor recently bought a new position in Bellicum Pharmaceuticals stock. HRT Financial LP bought a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned about 0.42% of Bellicum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 4.93% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.
Recommended Stories
- Five stocks we like better than Bellicum Pharmaceuticals
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- United Airlines Soars on Earnings Beat
- CD Calculator: Certificate of Deposit Calculator
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.